Status:
COMPLETED
Sodium-Endothelial Function-CKD Study
Lead Sponsor:
St George's, University of London
Collaborating Sponsors:
British Heart Foundation
St. George's Hospital Charitable Foundation
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Heart disease and stroke, known as cardiovascular disease, are major causes of death in people with chronic kidney disease. Abnormalities of a metabolic pathway called the "L-arginine-nitric oxide" pa...
Detailed Description
Chronic kidney disease (CKD) is associated with abnormalities of endothelial function (EF) and nitric oxide (NO) synthesis, and it is proposed that the endogenous NO synthase inhibitor asymmetrical di...
Eligibility Criteria
Inclusion
- CKD Stages 2 and 3 \[= calculated creatinine clearance of 30 to 89 ml/min/1.73m2 by Cockcroft-Gault formula\]
- 18 to 75 years old
Exclusion
- \>3 g/24 hours of proteinuria
- Uncontrolled hypertension (systolic BP \>160 mmHg, diastolic BP \>100 mmHg on/off anti-hypertensive medication)
- Diabetes mellitus
- Tobacco smoking
- Total fasting cholesterol \>6 mmol/L
- Uncontrolled heart failure or active IHD
- Chronic liver failure
- Active malignancy
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00141622
Start Date
April 1 2005
End Date
October 1 2006
Last Update
May 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood Pressure Unit, Department of Cardiac & Vascular Sciences, SGUL
London, United Kingdom, SW17 0RE